Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

Nuclear medicine plays an increasingly important role in the management neuroendocrine neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT) have been used in clinical trials and approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).European Association of Nuclear Medicine (EANM) Focus 3 performed a multidisciplinary Delphi process to deliver a balanced perspective on molecular imaging and radionuclide therapy in well-differentiated neuroendocrine tumours (NETs).

Source: European Journal of Cancer - February 12, 2021 Category: Cancer & Oncology Authors: Valentina Ambrosini, Jolanta Kunikowska, Eric Baudin, Lisa Bodei, Catherine Bouvier, Jaume Capdevila, Marta Cremonesi, Wouter W. de Herder, Clarisse Dromain, Massimo Falconi, Melpomeni Fani, Stefano Fanti, Rodney J. Hicks, Levent Kabasakal, Gregory Kaltsa Tags: Review Source Type: research